ArticleNPJ breast cancer2022
Stem-like breast cancer cells in the activated state resist genetic stress via TGFBI-ZEB1.
Article in NPJ breast cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 17 citations in OpenAlex.
- Tumor-derived ITGB3 shapes a primed but functionally constrained NK cell state in breast cancer through HLA-E-NKG2A signaling.Molecular biology reports · 2026Article
- The Oncogenic Role of Prostate Stem Cell Antigen (PSCA) in Colorectal Cancer: Implications for Targeted Therapy.Current issues in molecular biology · 2026Article
- The SRG rat as a novel host for an orthotopic patient-derived xenograft model of breast cancer brain metastasis.Scientific reports · 2025Article
- S100A8/A9 innate immune signaling as a distinct mechanism driving progression of smoking-related breast cancers.Oncogene · 2025Article
- FAT1 functions as an oncogenic driver in triple negative breast cancer through AKT pathway-driven effects on the matrisome.International journal of biological sciences · 2025Article
- Involvement of TGFBI-TAGLN axis in cancer stem cell property of head and neck squamous cell carcinoma.Scientific reports · 2024Article
- Targeted therapy approaches for epithelial-mesenchymal transition in triple negative breast cancer.Frontiers in oncology · 2024Review
- Chromosomal instability as an architect of the cancer stemness landscape.Frontiers in cell and developmental biology · 2024Review
- Tumor-on-chip platforms for breast cancer continuum concept modeling.Frontiers in bioengineering and biotechnology · 2024Review
- A dataset of chromosomal instability gene signature scores in normal and cancer cells from the human breast.Data in brief · 2023Article
- Article
- Breast cancer stem cells tolerate chromosomal instability during tumor progression via c-Jun/AXL stress signaling.Heliyon · 2023Article
- Clinical applications of 3D normal and breast cancer organoids: A review of concepts and methods.Experimental biology and medicine (Maywood, N.J.) · 2022Review
- Breast cancer stem cells: mechanobiology reveals highly invasive cancer cell subpopulations.Cellular and molecular life sciences : CMLS · 2022Article
- Mechanisms of Cell Adhesion Molecules in Endocrine-Related Cancers: A Concise Outlook.Frontiers in endocrinology · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 2 countries.
Funding
Abstract
Breast cancer cells with stem-like properties are critical for tumor progression, yet much about these cells remains unknown. Here, we characterize a population of stem-like breast cancer cells expressing the integrin αvβ3 as transcriptionally related to activated stem/basal cells in the normal human mammary gland. An unbiased functional screen of genes unique to these cells identified the matrix protein TGFBI (BIG-H3) and the transcription factor ZEB1 as necessary for tumorsphere formation. Surprisingly, these genes were not required for cell proliferation or survival, but instead maintained chromosomal stability. Consistent with this finding, CRISPR deletion of either gene synergized with PARP inhibition to deplete αvβ3
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.